Improved nerve visualization to reduce unintended intraoperative nerve injury

Illuminare Biotechnologies

Illuminare Biotechnologies is a preclinical stage biotechnology company focused on intra-operative nerve visualization to reduce the risk of nerve damage. Our proprietary lead candidate, Illuminare-1, is a small molecule with an immediate onset of action and sustained duration of nerve illumination. Illuminare-1 will enter the first in human phase 1 clinical trial in Q1 2021, following IND approval. Illuminare Biotechnologies is a privately held company founded in 2016.